U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. WILATE
  1. Approved Blood Products

WILATE

STN:  BL 125251
Proper Name: von Willebrand Factor/Coagulation Factor VIII Complex (Human)
Tradename: WILATE
Manufacturer: OCTAPHARMA Pharmazeutika Produktionsges.m.b.H.

Indication:

  • Selected Routine prophylaxis to reduce the frequency of bleeding episodes in patients with von Willebrand Disease.
  • In adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and for on-demand treatment and control of bleeding episodes.
  • for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.

Product Information

Supporting Documents

Back to Top